Lanre is a Managing Director at Chapel Hill Denham, Nigeria’s leading investment bank. He is one of the leading deal makers in the country by value of successfully completed transactions. He has over 23 years of experience across investment banking, corporate finance, infrastructure, and the healthcare sectors. As a capital market specialist, he has managed transformational transactions raising more than N12 trillion ($25 billion) for the Sovereign, sub-nationals, DFIs, SOEs, financial sponsors, and corporates across the equity and debt capital markets. Over the last decade, his collaborations with stakeholders in the ecosystem have helped further develop and deepen the Nigerian capital markets.
Before joining Chapel Hill Denham, Lanre was a pioneer member of the leadership team at Primera Africa where he held multiple roles across institutional sales, investment research, financial advisory, and securities brokerage. Before Primera, Lanre was an Equity Research Analyst at Bloomberg LP, covering the Biotechnology and Pharmaceutical industry. Prior to Bloomberg, Lanre worked as a corporate finance associate at Roche Pharmaceuticals working primarily on deal analysis, asset valuation, and strategic due diligence for global in-licensing opportunities and acquisitions of clinical-stage drug assets.
Lanre began his professional career as a molecular biochemist at Orchid Biosciences Inc. as a drug and diagnostic device development team member. He is a graduate of Molecular Biology & Biochemistry and Economics from Rutgers College as a Henry Rutgers Scholar. He holds an MBA from Rutgers Business School focused on Finance and Pharmaceutical Management.
